Literature DB >> 8519655

Determination of oestrogen responsiveness of breast cancer by competitive reverse transcription-polymerase chain reaction.

M Carr1, F E May, T W Lennard, B R Westley.   

Abstract

Competitive polymerase chain reaction assays have been developed for the quantitation of oestrogen receptor mRNA and two oestrogen-regulated mRNAs (progesterone receptor and pNR-2/pS2) in breast cancer cells. These assays are more sensitive than traditional hybridisation techniques, do not require the use of radioisotopes, measure absolute amounts of messenger RNAs and can be used to measure the expression of mRNAs in small numbers of tumour cells obtained by fine-needle aspiration (FNA). These assays should prove useful for predicting the hormone responsiveness of breast cancer from tumour cells obtained by FNA at diagnosis and could be particularly useful in the management of elderly/frail patients who receive primary tamoxifen, or in other patients for whom tumour tissue for standard biochemical measurements is not available.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8519655      PMCID: PMC2034093          DOI: 10.1038/bjc.1995.525

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

1.  Effects of tamoxifen and 4-hydroxytamoxifen on the pNR-1 and pNR-2 estrogen-regulated RNAs in human breast cancer cells.

Authors:  F E May; B R Westley
Journal:  J Biol Chem       Date:  1987-11-25       Impact factor: 5.157

2.  Cloning of estrogen-regulated messenger RNA sequences from human breast cancer cells.

Authors:  F E May; B R Westley
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

3.  Novel method for studying mRNA phenotypes in single or small numbers of cells.

Authors:  D A Rappolee; A Wang; D Mark; Z Werb
Journal:  J Cell Biochem       Date:  1989-01       Impact factor: 4.429

4.  Identification and characterization of estrogen-regulated RNAs in human breast cancer cells.

Authors:  F E May; B R Westley
Journal:  J Biol Chem       Date:  1988-09-15       Impact factor: 5.157

5.  Effects of oestrogen and the antioestrogens, tamoxifen and LY117018, on four oestrogen-regulated RNAs in the EFM-19 breast cancer cell line.

Authors:  B R Westley; F Hölzel; F E May
Journal:  J Steroid Biochem       Date:  1989-03       Impact factor: 4.292

6.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel; J D Roberts; R A Zakour
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

7.  Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer.

Authors:  J C Gazet; C Markopoulos; H T Ford; R C Coombes; J M Bland; R C Dixon
Journal:  Lancet       Date:  1988-03-26       Impact factor: 79.321

8.  Wound macrophages express TGF-alpha and other growth factors in vivo: analysis by mRNA phenotyping.

Authors:  D A Rappolee; D Mark; M J Banda; Z Werb
Journal:  Science       Date:  1988-08-05       Impact factor: 47.728

9.  Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates.

Authors:  R C Coombes; T J Powles; U Berger; P Wilson; R A McClelland; J C Gazet; P A Trott; H T Ford
Journal:  Lancet       Date:  1987-09-26       Impact factor: 79.321

10.  PCR expression analysis of the estrogen-inducible gene BCEI in gastrointestinal and other human tumors.

Authors:  I Wundrack; R Müllenbach; C Welter; G Seitz; N Blin
Journal:  Dis Markers       Date:  1994-10       Impact factor: 3.434

View more
  2 in total

1.  PS2 mRNA expression adds prognostic information to node status for 6-year survival in breast cancer.

Authors:  A M Thompson; R A Elton; R A Hawkins; U Chetty; C M Steel
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

2.  Changes in expression of estrogen receptors alpha and beta in relation to progesterone receptor and pS2 status in normal and malignant endometrium.

Authors:  M Saegusa; I Okayasu
Journal:  Jpn J Cancer Res       Date:  2000-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.